Promoting cost effective prescribing
BMJPublished 15 April 1995Open access
Nick Freemantle, David Henry, Alan Maynard, George W. Torrance
Citations43
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The message is clear: doctors may prescribe an effective drug to patients who will benefit, but if the drug is not cost effective they may be using resources that would produce greater benefit for other patients for the same cost.
Keywords
Economics, Econometrics and FinanceHealth Professions
Methods for the Economic Evaluation of Health Care Programmes
4,559 Citations2005Michael E Drummond, Mark J Sculpher +3 more
BMJSystematic Reviews: Rationale for systematic reviews
1,642 Citations1994Cynthia D. Mulrow
Systematic literature reviews establish whether scientific findings are consistent and can be generalised across populations, settings, and treatment variations, or whether findings vary significantly by particular subsets.
JAMAA Comparison of Results of Meta-analyses of Randomized Control Trials and Recommendations of Clinical Experts
1,464 Citations1992Elliott M. Antman
Finding and analyzing all therapeutic trials in a given field has become such a difficult and specialized task that the clinical experts called on to summarize the evidence in a timely fashion need access to better databases and new statistical techniques to assist them.
BMJThe scandal of poor medical research
872 Citations1994D G Altman
The authors need less research, better research, and research done for the right reasons, and researchers who use the wrong techniques, use the right techniques wrongly, misinterpret their results, report their results selectively, cite the literature selectively, and draw unjustified conclusions.
Controlled Clinical TrialsMethodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis
336 Citations1989Peter C Gøtzsche
Important design aspects were decreasingly reported in NSAID trials over the years, whereas the quality of statistical analysis improved, and it is not obvious how a reliable meta-analysis could be done in these trials.
Journal of Clinical EpidemiologyAssessing the clinical effectiveness of preventive maneuvers: Analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations A report by the Canadian task force on the periodic health examination
260 Citations1990Steven H. Woolf
This paper examines a process for evaluating clinical effectiveness and developing recommendations in which systematic methods are used to review evidence from published clinical research and to reach sound conclusions about appropriate medical policy.
New England Journal of MedicineAvoiding Bias in the Conduct and Reporting of Cost-Effectiveness Research Sponsored by Pharmaceutical Companies
238 Citations1991Alan L. Hillman, John M. Eisenberg +5 more
Because of the growing focus on containing health care costs, pharmaceutical companies are trying to demonstrate the cost effectiveness of their products relative to alternatives in Europe and Australia.
The British Journal of PsychiatryWhat Price Depression?
228 Citations1994Bengt Jönsson, Paul Bebbington
The model reveals that medication that appears expensive in terms of cost per day may not be so when patient compliance and the total costs of treatment are taken into account.
British Medical BulletinTHE COST-BENEFIT APPROACH
107 Citations1974Alan Williams
The planning process is the concern here and, in particular, one important, and increasingly wide-spread, approach to the problems that arise within it, namely, cost-benefit analysis.
BMJPrescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide
100 Citations1994Nick Freemantle, Allan House +3 more
The cost per life year gained through avoiding suicides by the routine first line use of serotonin reuptake inhibitors is likely to be high and the shift to considerably more expensive options must be further investigated.
American Heart JournalThe design of future cost-benefit studies
24 Citations1990Alan Maynard
An economic evaluation is designed to prioritize expenditure, aid decision making, and inform medical audit, and takes into consideration the cost of each component and measures outcome in economic benefit and physical, social, and psychologic well-being.
Health AffairsThe Pharmaceutical Industry and Health Reform: Lessons From Europe
23 Citations1994John Hutton, Michael J. Borowitz +2 more
The organizational models and regulatory approaches in Europe offer a useful store of experience for those assessing the potential impact of reform proposals in the United States.
BMJPrenatal screening for trisomy 18: Should not be contemplated
4 Citations1994T. Davies
The authors fail to emphasise the importance of the relative incidence of the two conditions at birth before concluding that screening for trisomy 18 should be introduced.
BMJSelective serotonin reuptake inhibitors Drugs related to tricyclic antidepressants are a mixed bag
4 Citations1994Philip J. Cowen, Christopher M. Thompson
Compared with selective serotonin reuptake inhibitors, “newer tricyclic and related antidepresants … will have similar impact on rates of suicide but at considerably less cost”.
Europe PMC (PubMed Central)Conflict of interest : Public funding should also be declared
1 Citations1994D P Doogan